Loading
YES1 (Tyrosine-protein kinase Yes) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Leukaemia and 5 more.
Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. Stimulation by receptor tyrosine kinases (RTKs) including EGFR, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR activation, promotes the phosphorylation of PARD3 to favor epithelial tight junction assembly.
CIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Neratinib, Dasatinib and CH6953755. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes literature 0.95, affected pathway 0.91, genetic association 0.37, clinical 0.96).
In plain words · YES1 (Tyrosine-protein kinase Yes) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Leukaemia and 5 more.
YES1 (Tyrosine-protein kinase Yes) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Leukaemia and 5 more.
Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation.
No product in this corpus aims at YES1 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA YES1: RNA low tissue specificity; blood lineage lineage enriched (granulocytes 20 nTPM); no normal tissue stained high; highest cancer staining colorectal cancer (1 of 12 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Lung cancer (all types), Leukaemia, Myeloid neoplasms, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (chronic myeloid leukemia, acute lymphoblastic leukemia). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas YES1 tissue; Open Targets ENSG00000176105 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: Sukegawa et al, Mol. Cell. Biol, 1987, "Characterization of cDNA clones for the human c-yes gene". Source.
Sources: HGNC HGNC:12841 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P07947 (protein name, function text, keywords and locations (REST API)); CIViC gene YES1 (3 evidence items, 0 assertions, 2 variants; diseases: Breast Cancer, Lung Cancer, Lung Small Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000176105 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.55, non-Hodgkin lymphoma 0.55, chronic myelogenous leukaemia, BCR-ABL1 positive 0.58, myeloproliferative neoplasm 0.58, leukaemia 0.59 (GraphQL API, CC0))
Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. Stimulation by receptor tyrosine kinases (RTKs) including EGFR, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR activation, promotes the phosphorylation of PARD3 to favor epithelial tight junction assembly. Participates in the phosphorylation of specific junctional components such as CTNND1 by stimulating the FYN and FER tyrosine kinases at cell-cell contacts. Upon T-cell stimulation by CXCL12, phosphorylates collapsin response mediator protein 2/DPYSL2 and induces T-cell migration. Participates in CD95L/FASLG signalling pathway and mediates AKT-mediated cell migration. Location: Cell membrane; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cytoplasm, cytosol; Cell junction (UniProt). Locus 18p11.32 (HGNC).
RNA: low tissue specificity, detected in all normal tissues. Blood: lineage enriched (granulocytes 20 nTPM).
No normal tissue stained high; medium in Adipose tissue, Adrenal gland, Appendix, Breast, Bronchus, Caudate and more.
Medium only: breast cancer, carcinoid, cervical cancer, endometrial cancer.
HPA YES1 tissue · HPA YES1 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"YES1" OR ABSTRACT:"YES1" OR TITLE:"YES proto-oncogene 1, Src family tyrosine kinase" OR ABSTRACT:"YES proto-oncogene 1, Src family tyrosine kinase" OR TITLE:"Tyrosine-protein kinase Yes" OR ABSTRACT:"Tyrosine-protein kinase Yes" OR TITLE:"Yes" OR ABSTRACT:"Yes" OR TITLE:"c-yes" OR ABSTRACT:"c-yes" OR TITLE:"HsT441" OR ABSTRACT:"HsT441") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about YES1, not a curated reading list.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, Breast cancer (all types).
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Lung cancer (all types).
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Lung cancer (all types).
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Lung cancer (all types).
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Lung cancer (all types).